Premium
Dose‐related effects of phenobarbitone on human sleep‐waking patterns.
Author(s) -
Karacan I,
Orr W,
Roth T,
Kramer M,
Thornby J,
Bingham S,
Kay D
Publication year - 1981
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1981.tb01218.x
Subject(s) - morning , sleep (system call) , sedation , placebo , anesthesia , medicine , electroencephalography , audiology , psychiatry , operating system , alternative medicine , pathology , computer science
1 Twenty‐four healthy male subjects had two consecutive drug nights at 2‐week intervals using placebo and 80, 140 and 240 mg doses of phenobarbitone in a double‐blind cross‐over design. 2 Phenobarbitone produced significant dose‐related decreases in sleep latency and number of awakenings, along with increased total sleep time. 3 Both subjective and objective measures of sleep indicated the presence of cumulative (first v second night) effects of phenobarbitone, especially decreases in the number of awakenings and in delta waveform activity. 4 Measures of REM sleep were highly sensitive to phenobarbitone. The high dose decreased REM density to 30% of baseline on the first night and to 18% on the second night. 5 EEG alpha activity was decreased, beta activity was increased and sigma spindle activity was unaffected by phenobarbitone during sleep. 6 Subjects experienced some impairment of cognitive performance along with residual sedation the following morning.